These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3826055)

  • 1. Effectiveness of oral iron chelators assayed in the rat.
    Kim BK; Huebers HA; Finch CA
    Am J Hematol; 1987 Mar; 24(3):277-84. PubMed ID: 3826055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
    Baker E; Vitolo ML; Webb J
    Biochem Pharmacol; 1985 Sep; 34(17):3011-7. PubMed ID: 4038321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
    Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
    Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid assay for evaluation of iron-chelating agents in rats.
    Pippard MJ; Johnson DK; Finch CA
    Blood; 1981 Oct; 58(4):685-92. PubMed ID: 7272500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
    Richardson DR; Ponka P
    J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
    Bláha K; Cikrt M; Nerudová J; Ponka HF
    Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
    Richardson DR; Milnes K
    Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs.
    Richardson DR; Ponka P
    J Lab Clin Med; 1998 Oct; 132(4):351-2. PubMed ID: 9794707
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone.
    Ponka P; Grady RW; Wilczynska A; Schulman HM
    Biochim Biophys Acta; 1984 Dec; 802(3):477-89. PubMed ID: 6509088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
    Cikrt M; Ponka P; Necas E; Neuwirt J
    Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes.
    Buss JL; Arduini E; Ponka P
    Biochem Pharmacol; 2002 Dec; 64(12):1689-701. PubMed ID: 12445858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
    Hershko C; Avramovici-Grisaru S; Link G; Gelfand L; Sarel S
    J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells.
    Buss JL; Arduini E; Shephard KC; Ponka P
    Biochem Pharmacol; 2003 Feb; 65(3):349-60. PubMed ID: 12527328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chelators on iron uptake and release by the brain in the rat.
    Crowe A; Morgan EH
    Neurochem Res; 1994 Jan; 19(1):71-6. PubMed ID: 8139766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
    Gao J; Richardson DR
    Blood; 2001 Aug; 98(3):842-50. PubMed ID: 11468187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aging-related changes in the iron status of skeletal muscle.
    DeRuisseau KC; Park YM; DeRuisseau LR; Cowley PM; Fazen CH; Doyle RP
    Exp Gerontol; 2013 Nov; 48(11):1294-302. PubMed ID: 23994517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical studies of pyridoxal isonicotinoyl hydrazone relevant to its clinical evaluation.
    Vitolo ML; Clare BW; Hefter GT; Webb J
    Birth Defects Orig Artic Ser; 1988; 23(5B):71-9. PubMed ID: 3390576
    [No Abstract]   [Full Text] [Related]  

  • 18. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease.
    Richardson DR; Ponka P
    J Lab Clin Med; 1998 Apr; 131(4):306-15. PubMed ID: 9579383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenolic ethylenediamine derivatives: a study of orally effective iron chelators.
    Hershko C; Grady RW; Link G
    J Lab Clin Med; 1984 Mar; 103(3):337-46. PubMed ID: 6699459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone.
    Hoy T; Humphrys J; Jacobs A; Williams A; Ponka P
    Br J Haematol; 1979 Nov; 43(3):443-9. PubMed ID: 497121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.